VYNE Therapeutics Inc. — Form 8-K
Filed July 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 92/100
What the filing says
VYNE Therapeutics is merging with Yarrow Bioscience (closing expected July 24, 2026). VYNE Board approved a 1-for-50 reverse stock split, reducing outstanding shares from 33.4M to 0.7M. VYNE shareholders receive a special cash dividend of $17.3 million aggregate ($0.40242 per share based on 42.99M shares outstanding as of July 20, 2026), payable July 23, 2026. Post-merger combined company will trade under ticker YARW on Nasdaq Capital Market with approximately 2.7M shares outstanding (33.6M fully diluted).
Why this rating
Merger fundamentally restructures VYNE (transforms into Yarrow), reverse split and $17.3M dividend represent 54% of company's $32M market cap. Business-changing event; outcome depends on merger value and combined entity viability.
See more from July 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.